BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burt T, Vuong LT, Baker E, Young GC, McCartt AD, Bergstrom M, Sugiyama Y, Combes R. Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development. Altern Lab Anim 2018;46:335-46. [PMID: 30657329 DOI: 10.1177/026119291804600603] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Hou L, Rong J, Haider A, Ogasawara D, Varlow C, Schafroth MA, Mu L, Gan J, Xu H, Fowler CJ, Zhang MR, Vasdev N, Ametamey S, Cravatt BF, Wang L, Liang SH. Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development. J Med Chem 2021;64:123-49. [PMID: 33379862 DOI: 10.1021/acs.jmedchem.0c01459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Van Norman GA. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach? JACC Basic Transl Sci 2019;4:845-54. [PMID: 31998852 DOI: 10.1016/j.jacbts.2019.10.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 13.7] [Reference Citation Analysis]
3 Ahsan H. Monoplex and multiplex immunoassays: approval, advancements, and alternatives. Comp Clin Path 2022;31:333-45. [PMID: 34840549 DOI: 10.1007/s00580-021-03302-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M, Sugiyama Y. Phase 0/microdosing approaches: time for mainstream application in drug development? Nat Rev Drug Discov 2020;19:801-18. [PMID: 32901140 DOI: 10.1038/s41573-020-0080-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
5 Xue R, Li R, Wang J, Tong W, Hao J. Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review. J Clin Transl Hepatol 2021;9:559-67. [PMID: 34447686 DOI: 10.14218/JCTH.2021.00007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 van Groen BD, van Duijn E, de Vries A, Mooij MG, Tibboel D, Vaes WHJ, de Wildt SN. Proof of Concept: First Pediatric [14 C]microtracer Study to Create Metabolite Profiles of Midazolam. Clin Pharmacol Ther 2020;108:1003-9. [PMID: 32386327 DOI: 10.1002/cpt.1884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Schreiber CL, Li DH, Smith BD. High-Performance Near-Infrared Fluorescent Secondary Antibodies for Immunofluorescence. Anal Chem 2021;93:3643-51. [PMID: 33566567 DOI: 10.1021/acs.analchem.1c00276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang X, Chen J, Reyes J, Zhou S, Palmisano M, Li Y. A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach. Oncol Ther 2020;8:91-102. [PMID: 32700065 DOI: 10.1007/s40487-019-0097-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]